Don't believe I've come across a biotech/biopharma company with positive Ph2a data in a global indication with a market cap of less than $20m before. Truly astounding...
The pharmacokinetic study evaluating the modified release DMX-200 must be underway now. Expecting an update on this study in the near term- with completion stated to be prior to year end.
At current mc of $15m, I'd love to take this company private, complete the Ph2b and license the program for $200+m in 18-24 months time..
Can anyone chip in with me?? hehe..
DXB- Most Undervalued Biotech on ASX?
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26318 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 170072 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |